Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.

about

Lenvatinib enhances the antitumor effects of paclitaxel in anaplastic thyroid cancer An overview of quinoline as a privileged scaffold in cancer drug discovery.A novel multikinase inhibitor R8 exhibits potent inhibition on cancer cells through both apoptosis and autophagic cell death.

P2860

Q33622678-5545DAC0-8231-4FFD-A63B-C82A981CC5EC Q39235281-A88F55A6-E570-442E-B38C-6965FA6DFC4B Q44869860-8D5D3C6A-8480-4CCA-A51B-171A0B839049

P2860

Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.

Item

http://www.wikidata.org/entity/Q39011379

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年論文

@yue

2016年論文

@zh-hant

2016年論文

@zh-hk

2016年論文

@zh-mo

2016年論文

@zh-tw

2016年论文

@wuu

2016年论文

@zh

2016年论文

@zh-cn

name

Lenvatinib - A multikinase inh ...... differentiated thyroid cancer.

@en

Lenvatinib - A multikinase inh ...... differentiated thyroid cancer.

@nl

type

Item

label

Lenvatinib - A multikinase inh ...... differentiated thyroid cancer.

@en

Lenvatinib - A multikinase inh ...... differentiated thyroid cancer.

@nl

prefLabel

Lenvatinib - A multikinase inh ...... differentiated thyroid cancer.

@en

Lenvatinib - A multikinase inh ...... differentiated thyroid cancer.

@nl

P1476

Lenvatinib - A multikinase inh ...... differentiated thyroid cancer

@en

P2093

Binay K Shah

http://www.w3.org/2001/XMLSchema#string

Subash Ghimire

http://www.w3.org/2001/XMLSchema#string

Yvonne Hewett

http://www.w3.org/2001/XMLSchema#string

P2860

Cell signaling by receptor tyrosine kinases

Lenvatinib: Role in thyroid cancer and other solid tumors

Cell signaling by receptor tyrosine kinases

2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer

Phase 1 study of lenvatinib combined with carboplatin and paclitaxel in patients with non-small-cell lung cancer.

A phase 1 study of lenvatinib, multiple receptor tyrosine kinase inhibitor, in Japanese patients with advanced solid tumors.

Effect of rifampicin on the pharmacokinetics of lenvatinib in healthy adults.

Effects of Ketoconazole on the Pharmacokinetics of Lenvatinib (E7080) in Healthy Participants

A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumours

A phase 1b clinical trial of the multi-targeted tyrosine kinase inhibitor lenvatinib (E7080) in combination with everolimus for treatment of metastatic renal cell carcinoma (RCC).

P304

28-32

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1078155216680119

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Bilal Farooqi

P577

2016-11-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27856921

http://www.w3.org/2001/XMLSchema#string

Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.

about

P2860

P2860

Lenvatinib - A multikinase inhibitor for radioiodine-refractory differentiated thyroid cancer.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698